NanoViricides, Inc. is a nano-biopharmaceutical research and development company. The Company is engaged the discovery, development, and commercialization of drugs to combat viral infections using its nanomedicines technology. The Company provides nanoviricide technology, which enables direct attacks at multiple points on a virus particle. The nanoviricide technology is engaged in both attacking extracellular virus thereby breaking the reinfection cycle, and simultaneously disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. The nanoviricide technology also simultaneously enables attacking the intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. The Company’s lead product candidate is NV-HHV-101 in the HerpeCide program, as a skin cream for the treatment of shingles rash.